The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
BLA vs. NDA: Understanding the Differences in Biopharmaceutical Approvals
Read More
post
A CMC Consultant’s Critical Role in Successful Regulatory Submissions
Read More
post
How CMC Consulting Accelerates Product Development Timelines
Read More
post
CMC Manufacturing and Its Impact on FDA Approvals
Read More
Let's move from science to success.
Let’s Talk